Correlation of Levator-Muller's Complex Thickness on Ultrasound Biomicroscopy to Botulinum Toxin A Injection in Thyroid-Related Upper Eyelid Retraction.
UBM
botulinum
eyelid
levator aponeurosis
retraction
thyroid eye disease
Journal
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
ISSN: 1550-9613
Titre abrégé: J Ultrasound Med
Pays: England
ID NLM: 8211547
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
21
04
2022
received:
15
02
2022
accepted:
01
05
2022
pubmed:
14
5
2022
medline:
24
1
2023
entrez:
13
5
2022
Statut:
ppublish
Résumé
To study the thickness of levator palpebra superioris-Muller's muscle complex (LMC) on ultrasound biomicroscopy (UBM) and to correlate with the clinical response to botulinum toxin A (BTA) injection in patients with inactive-stage of thyroid-related upper eyelid retraction (UER). We also studied the correlation of clinical parameters, preinjection with postinjection values. This was a prospective, interventional study. Patients with thyroid-related UER who underwent subconjunctival injection of BTA were recruited. Demographic data and clinical details were evaluated. UBM (50 MHz) was done to measure the thickness of LMC. Patient's satisfaction was graded at each follow-up. Follow-up was done at 1 week, 1 month, and 3 months' time intervals. A total of 13 patients were recruited and 26 eyes were divided into two groups; group 1 included eyes with UER (n = 17), and group 2 included eyes without UER (n = 9). There was a statistically significant reduction in margin reflex distance 1 (MRD1) after BTA injection at 1-week, 1-month, and 3-months follow-up with maximum reduction at 1 month. The mean LMC thickness of 26 eyes was 0.96 mm which was found to be significantly more than normal controls. On comparison of mean LMC thickness with the amount of UER and reduction in MRD1, we did not find a significant difference. Patients with TED have significantly thicker LMC on UBM than controls. Further studies are needed with a larger sample size on the correlation of UBM features of levator aponeurosis with response to BTA injection.
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
399-408Informations de copyright
© 2022 American Institute of Ultrasound in Medicine.
Références
Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121:284-290.
Lee DC, Young SM, Kim YD, Woo KI. Course of upper eyelid retraction in thyroid eye disease. Br J Ophthalmol 2020; 104:254-259.
Bajaj MS, Aalok L, Gupta V, et al. Ultrasound biomicroscopic appearances of eyelid lesions at 50 MHz. J Clin Ultrasound 2007; 35:424-429.
Al-Faky YH. Anatomical utility of ultrasound biomicroscopy in the lacrimal drainage system. Br J Ophthalmol 2011; 95:1446-1450.
Surve A, Meel R, Pushker N, Bajaj MS. Ultrasound biomicroscopy image patterns in normal upper eyelid and congenital ptosis in the Indian population. Indian J Ophthalmol 2018; 66:383-388.
Ozturk Karabulut G, Fazil K, Saracoglu Yilmaz B, et al. An algorithm for Botulinum toxin A injection for upper eyelid retraction associated with thyroid eye disease: long-term results. Orbit 2021; 40:268.
Nava Castañeda A, Tovilla Canales JL, Garnica Hayashi L, Velasco Y, Levy A. Traitement de la rétractionpalpébrale supérieure associée à l'ophtalmopathiedysthyroïdienneen phase active inflammatoire avec l'injection de toxinebotulique A [Management of upper eyelid retraction associated with dysthyroid orbitopathy during the acute inflammatory phase with botulinum toxin type A]. J Fr Ophtalmol 2017; 40:279-284.
Salour H, Bagheri B, Aletaha M, et al. Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease. Orbit 2010; 29:114-118.
Costa PG, Saraiva FP, Pereira IC, et al. Comparative study of Botox injection treatment for upper eyelid retraction with 6-month follow-up in patients with thyroid eye disease in the congestive or fibrotic stage. Eye (Lond) 2009; 23:767-773.
Costa PG, Saraiva FP, Matayoshi S. Análisemorfométrica da fenda palpebral de pacientes com oftalmopatiadistireóidea antes e apósaplicação de toxinabotulínicatipo A [Morphometric analysis of the palpebral fissure in patients with thyroid-related disfunction before and after application of botulinum toxin]. Arq Bras Endocrinol Metabol 2006; 50:920-925.
Costa PG, Saraiva FP, Pereira IC, Matayoshi S. Análisemorfométrica da fenda palpebral de pacientes com retração palpebral nafaseaguda da orbitopatiadistireoidianasubmetidos à injeção palpebral de toxinabotulínicatipo A [Morphometric analysis of eyelid fissure in patients with eyelid retraction in acute stage of dysthyroid orbitopathy after treatment with botulinum toxin type A]. Arq Bras Oftalmol 2008; 71:480-485.
Dintelmann T, Sold J, Grehn F. Transkonjunktivale Botulinumtoxininjektion zur Behandlung der Oberlidretraktion bei endokriner Orbitopathie [Botulinum toxin injection-treatment of upper lid retraction in thyroid eye disease]. Ophthalmologe 2005; 102:247-250.
Morgenstern KE, Evanchan J, Foster JA, et al. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthalmic PlastReconstr Surg 2004; 20:181-185.
Shih MJ, Liao SL, Lu HY. A single transcutaneous injection with Botox for dysthyroid lid retraction. Eye (Lond) 2004; 18:466-469.
Ebner R. Botulinum toxin type A in upper lid retraction of Graves' ophthalmopathy. J Clin Neuroophthalmol 1993; 13:258-261.
Lazarus JH. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease. Best Pract Res Clin Endocrinol Metab 2012; 26:273-279.
Li D, Sun F. Observations on the efficacy of two methods for the treatment of upper eyelid retraction in thyroid-associated ophthalmopathy. Biomed Res Int 2021; 18:9514279.
Hassan Hussien M, Abd El-Wahed Hassan E, El-Haddad NSEM. Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction. Ther Adv Ophthalmol 2020; 28:2515841420979113.
Smith TJ, Hegedüs L. Graves' disease. N Engl J Med 2016; 375:1552-1565.
Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 2002; 109:1183-1187.
Wabbels B, Förl M. Botulinum toxin bei Uberfunktion der Tränendrüse, spastischem Entropium und Ober lid retraktion beiendokriner Orbitopathie [Botulinum toxin treatment for crocodile tears, spastic entropion and for dysthyroid upper eyelid retraction]. Ophthalmologe 2007; 104:771-776.
Biglan AW. Control of eyelid retraction associated with Graves' disease with botulinum A toxin. Ophthalmic Surg 1994; 25:186-188.
Gaddipati RV, Meyer DR. Eyelid retraction, lid lag, lagophthalmos, and von Graefe's sign quantifying the eyelid features of Graves' ophthalmopathy. Ophthalmology 2008; 115:1083-1088.
Scott AB. Injection treatment of endocrine orbital myopathy. Doc Ophthalmol 1984; 58:141-145.
Lelli GJ Jr, Duong JK, Kazim M. Levator excursion as a predictor of both eyelid lag and lagophthalmos in thyroid eye disease. Ophthalmic PlastReconstr Surg 2010; 26:7-10.
Phelps PO, Williams K. Thyroid eye disease for the primary care physician. Dis Mon 2014; 60:292-298.
Koornneef L. Eyelid and orbital fascial attachments and their clinical significance. Eye (Lond) 1988; 2:130-134.
Selter JH, Gire AI, Sikder S. The relationship between Graves' ophthalmopathy and dry eye syndrome. Clin Ophthalmol 2014; 31:57-62.
Demirci H, Nelson CC. Ultrasound biomicroscopy of the upper eyelid structures in normal eyelids. Ophthalmic PlastReconstr Surg 2007; 23:122-125.